U.S. RESEARCH ROUNDUP- Equifax, Microstrategy, Netflix

Reuters
2024-11-19

Nov 19 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Equifax, Microstrategy and Netflix, on Tuesday.

HIGHLIGHTS

* Caseys General Stores Inc : Jefferies raises target price to $470 from

$450

* Equifax Inc : JP Morgan cuts target price to $283 from $304

* Microstrategy Inc : Benchmark raises target price to $450 from $300

* Netflix Inc : Jefferies raises target price to $1,000 from $800

* Palo Alto Networks Inc : Jefferies raises target price to $450 from $400

Following is a summary of research actions on U.S. companies reported by Reuters on Tuesday. Stock entries are in alphabetical order.

* Aclaris Therapeutics Inc : BTIG raises to buy from neutral

* Aclaris Therapeutics Inc : Jefferies raises to buy from hold

* Aclaris Therapeutics Inc : Jefferies raises target price to $7 from $2

* Aclaris Therapeutics Inc : Piper Sandler raises to overweight from neutral

* Aclaris Therapeutics Inc : Piper Sandler raises target price to $13 from $3

* Arvinas : Stephens initiates coverage with overweight rating; target price $55

* Beacon Roofing Supply Inc : JP Morgan raises target price to $136 from $119

* C4 Therapeutics : Stephens initiates coverage with equal-weight rating; PT $4

* Caseys General Stores Inc : Jefferies raises target price to $470 from $450

* Catalyst Pharmaceuticals : Stephens initiates coverage with overweight rating; PT $35

* Chargepoint Holdings Inc : HSBC cuts target price to $1.2 from $2

* Copart Inc : JP Morgan raises target price to $60 from $55

* Cullinan Therapeutics Inc : Jonestrading raises target price to $34 from $29

* Dime Community Bancshares : Stephens raises to overweight from equal-weight

* Dime Community Bancshares : Stephens raises target price to $39 from $30

* Enhabit Inc : Jefferies cuts target price to $8.25 from $8.75

* Equifax Inc : JP Morgan cuts target price to $283 from $304

* Fennec Pharmaceuticals : Stephens initiates coverage with overweight rating; PT $15

* Fortinet Inc : Piper Sandler raises target price to $100 from $80

* Franco-Nevada Corp : UBS initiates coverage with buy rating; target price $160

* Ideaya Biosciences : Stephens initiates coverage with overweight rating; PT $51

* Kemper Corp : TD Cowen raises target price to $84 from $72

* Kraft Heinz : Piper Sandler cuts to neutral from overweight

* Kraft Heinz : Piper Sandler cuts target price to $35 from $40

* Kymera Therapeutics : Stephens initiates coverage with overweight rating; PT $65

* Lovesac Co : Roth MKM raises target price to $35 from $31

* Methanex Corp : Piper Sandler raises target price to $71 from $68

* Microstrategy Inc : Benchmark raises target price to $450 from $300

* Microstrategy Inc : TD Cowen raises target price to $392 from $385

* Moderna : Berenberg initiates coverage with hold rating; target price $42

* Mosaic Co : Berenberg raises target price to $32 from $30

* Netflix Inc : Jefferies raises target price to $1,000 from $800

* Netflix Inc : Wedbush raises target price to $950 from $800

* Palo Alto Networks Inc : Jefferies raises target price to $450 from $400

* Plug Power Inc : HSBC cuts target price to $3.7 from $7.1

* PTC Therapeutics Inc : JP Morgan raises target price to $62 from $51

* Quantumscape Corp : HSBC raises target price to $5.3 from $4.7

* Quantumscape Corp : HSBC raises to hold from reduce

* Ready Capital Corp : KBW cuts target price to $6.75 from $7

* Reddit : Piper Sandler raises target price to $150 from $115

* Regenxbio Inc : Leerink Partners raises target price to $38 from $34

* Suncor Energy Inc : UBS raises target price to C$65 from C$61

* Vertiv Holdings Co : Jefferies raises target price to $145 from $125

* Williams-Sonoma Inc : JP Morgan raises target price to $145 from $136

(Compiled by Bengaluru Newsroom)

((Diaries@thomsonreuters.com))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10